


## CLAIMS

1. A compound of the Formula I



Formula I

wherein:

R1 is NHR10, (substituted or unsubstituted C<sub>1</sub>-C<sub>6</sub>alkyl)NHR10 or (unsubstituted or substituted C<sub>3</sub>-C<sub>8</sub>cycloalkyl)NHR10;

R10 is hydrogen, C<sub>1</sub>-C<sub>6</sub>alkyl, C<sub>1</sub>-C<sub>6</sub>alkyl(OH), C<sub>1</sub>-C<sub>6</sub>alkylidenyl(OH)R11, or an amino protecting group;

R11 is C<sub>1</sub>-C<sub>6</sub>alkyl, C<sub>2</sub>-C<sub>6</sub>alkenyl, C<sub>1</sub>-C<sub>6</sub>alkyl(O)C<sub>1</sub>-C<sub>6</sub>alkyl, C(O)O-C<sub>1</sub>-C<sub>6</sub>alkyl, aryl, or C<sub>1</sub>-C<sub>6</sub>alkylaryl;

R2 is hydrogen, C<sub>1</sub>-C<sub>6</sub>alkyl, aryl, or C<sub>1</sub>-C<sub>6</sub>alkylaryl;

R4 is hydrogen, C<sub>1</sub>-C<sub>6</sub>alkyl, aryl, C<sub>1</sub>-C<sub>6</sub>alkylaryl, or C<sub>2</sub>-C<sub>6</sub>alkenyl;

R5 is hydrogen, aryl, C<sub>1</sub>-C<sub>6</sub>alkylaryl, hydroxy, C<sub>1</sub>-C<sub>6</sub>alkoxy, unsubstituted or substituted C<sub>1</sub>-C<sub>6</sub>alkyl;

R6 and R7 are independently hydrogen, unsubstituted or substituted C<sub>1</sub>-C<sub>6</sub>alkyl, unsubstituted or substituted C<sub>2</sub>-C<sub>6</sub>alkenyl, or R6 and R7 together with the carbon atom to which they are attached form a carbocyclic ring of up to 8 atoms which is optionally partly unsaturated or a substituted C<sub>3</sub>-C<sub>8</sub> cycloalkyl group which is optionally partly unsaturated;

R8 is hydrogen, unsubstituted or substituted C<sub>1</sub>-C<sub>6</sub>alkyl, unsubstituted or substituted aryl, unsubstituted or substituted (C<sub>1</sub>-C<sub>6</sub>alkyl)C<sub>3</sub>-C<sub>8</sub>cycloalkyl, or unsubstituted or substituted C<sub>1</sub>-C<sub>6</sub>alkylaryl;

5 Q is -S(O)<sub>2</sub>- or -C(O)-;

m is a number selected from 1 or 2;


R3 is substituted C<sub>1</sub>-C<sub>6</sub>alkylaryl, substituted C<sub>1</sub>-C<sub>6</sub>alkyl(O)-C<sub>1</sub>-C<sub>6</sub>alkylaryl, substituted C<sub>3</sub>-C<sub>8</sub> cycloalkyl, substituted (C<sub>1</sub>-C<sub>6</sub> alkyl) C<sub>3</sub>-C<sub>8</sub> cycloalkyl, or aryl  
10 substituted by at least one -SO<sub>2</sub>CF<sub>3</sub> group; and R9 is hydrogen, C<sub>1</sub>-C<sub>6</sub>alkyl, C<sub>2</sub>-C<sub>6</sub>alkenyl, C<sub>2</sub>-C<sub>6</sub>alkynyl, C<sub>3</sub>-C<sub>8</sub>cycloalkyl, C<sub>3</sub>-C<sub>8</sub>cycloalkenyl, cyano, optionally substituted aryl, optionally substituted -O-aryl, optionally substituted -N-aryl, optionally substituted -S-aryl, -aryl-aryl(K1)(K2), -O-aryl-aryl(K1)(K2), -N-aryl-aryl(K1)(K2), -S-aryl-aryl(K1)(K2), -O-C<sub>1</sub>-C<sub>6</sub>alkyl, or C<sub>1</sub>-C<sub>6</sub>alkylaryl, wherein  
15 K1 is halo or -CF<sub>3</sub>, and K2 is hydrogen, halo or -CF<sub>3</sub> or K1 and K2 together form a methylenedioxy group; or

R3 is optionally substituted aryl, C<sub>1</sub>-C<sub>6</sub>alkylaryl, C<sub>1</sub>-C<sub>6</sub>alkyl(O)-C<sub>1</sub>-C<sub>6</sub>alkylaryl, C<sub>3</sub>-C<sub>8</sub> cycloalkyl, (C<sub>1</sub>-C<sub>6</sub> alkyl) C<sub>3</sub>-C<sub>8</sub> cycloalkyl; and R9 is aryl substituted by at least one -SO<sub>2</sub>CF<sub>3</sub> group, -O-aryl substituted by at least one -SO<sub>2</sub>CF<sub>3</sub> group, -N-aryl substituted by at least one -SO<sub>2</sub>CF<sub>3</sub> group, or  
20 -S-aryl substituted by at least one -SO<sub>2</sub>CF<sub>3</sub> group;

25 or a pharmaceutically acceptable salt or solvate thereof.

2. A compound according to claim 1 having Formula II

-178-



Formula II

wherein

5           R1, R2, R3, R5, R6, R7, R8, R9 and Q are as defined in claim 1 or a pharmaceutically acceptable salt or solvate thereof.

3.    A compound according to claim 1 or 2 wherein R3 is  
10   selected from substituted C<sub>1</sub>-C<sub>6</sub>alkylaryl, substituted C<sub>1</sub>-C<sub>6</sub>alkyl(O)-C<sub>1</sub>-C<sub>6</sub>alkylaryl, substituted (C<sub>1</sub>-C<sub>6</sub> alkyl) C<sub>3</sub>-C<sub>8</sub> cycloalkyl; or a pharmaceutically acceptable salt or solvate thereof.

15       4.    A compound according to claim 3 wherein the substituted C<sub>1</sub>-C<sub>6</sub>alkylaryl or substituted C<sub>1</sub>-C<sub>6</sub>alkyl(O)-C<sub>1</sub>-C<sub>6</sub>alkylaryl group contains an aryl moiety selected from phenyl, thiazolyl, pyridyl, naphthyl, thienyl, oxazolyl, isoxazolyl and indolyl which is substituted by from one to  
20   three groups independently selected from C<sub>1</sub>-C<sub>6</sub> alkyl, -OC<sub>1</sub>-C<sub>6</sub> alkyl, -OCF<sub>3</sub>, amide, aryl, aryloxy, SO<sub>2</sub>(C<sub>1-6</sub> alkyl), SO<sub>2</sub>CF<sub>3</sub>, NHamide, carboxamide, sulfonamide, NHsulfonamide, imide, hydroxy, carboxy, nitro, halo, tri(chloro or fluoro)methyl, and cyano; or a pharmaceutically acceptable  
25   salt or solvate thereof.

5. A compound according to any one of claims 1 to 4 wherein R<sub>3</sub> is a substituted C<sub>1</sub>-C<sub>6</sub> alkylaryl group or a substituted C<sub>1</sub>-C<sub>6</sub>alkyl(O)-C<sub>1</sub>-C<sub>6</sub>alkyl aryl group wherein:

the C<sub>1</sub>-C<sub>6</sub>alkyl moiety within the substituted C<sub>1</sub>-C<sub>6</sub> alkylaryl group is methyl, ethyl or propyl;

the C<sub>1</sub>-C<sub>6</sub>alkyl(O)-C<sub>1</sub>-C<sub>6</sub>alkyl moiety within the substituted C<sub>1</sub>-C<sub>6</sub>alkyl(O)-C<sub>1</sub>-C<sub>6</sub>alkyl aryl group is a moiety of formula -CH<sub>2</sub>OCH<sub>2</sub>-;


the substituted aryl moiety is 2-fluorophenyl, 3-fluorophenyl, 4-fluorophenyl, 2,3-difluorophenyl, 2,4-difluorophenyl, 2,5-difluorophenyl, 2,6-difluorophenyl, 3,4-difluorophenyl, 3,5-difluorophenyl, 2,4,6-trifluorophenyl, 2,3,4-trifluorophenyl, 2,4,5-trifluorophenyl, 2,3,6-trifluorophenyl, 2,3,5-trifluorophenyl, 2-chlorophenyl, 3-chlorophenyl, 4-chlorophenyl, 2,6-dichlorophenyl, 2,3-dichlorophenyl, 2,4-dichlorophenyl, 2,5-dichlorophenyl, 2-chloro-4-fluorophenyl, 2-methylphenyl, 2,6-difluoro-3-methylphenyl, 3,6-difluoro-2-chlorophenyl, 2-fluoro-6-chlorophenyl, 2-fluoro-3-chlorophenyl, 2-fluoro-4-chlorophenyl, 2,6-difluoro-3-chlorophenyl, 4-trifluoromethylphenyl, 3-trifluoromethylphenyl, 2-trifluoromethylphenyl, 2-fluoro-5-trifluoromethylphenyl, 2-fluoro-3-trifluoromethylphenyl, 2-fluoro-6-trifluoromethylphenyl, 2-chloro-3-trifluoromethylphenyl, 4-trifluoromethoxyphenyl, 3-trifluoromethoxyphenyl, 2-trifluoromethoxyphenyl, 2-cyanophenyl, 3-cyanophenyl, 4-cyanophenyl, 4-methanesulphonylphenyl, or 2-methylthiazolyl;

or a pharmaceutically acceptable salt or solvate thereof.

30


6. A compound according to any one of claims 1 to 5 wherein R<sub>1</sub> is

-180-



or a pharmaceutically acceptable salt or solvate thereof.

7. A compound according to any one of claims 1 to 5 wherein R<sub>1</sub> is selected from -C(CH<sub>2</sub>F)<sub>2</sub>NH<sub>2</sub>, -C(CH<sub>2</sub>F)(CH<sub>2</sub>CH<sub>2</sub>F)NH<sub>2</sub>, -C(CF<sub>3</sub>)(CH<sub>3</sub>)NH<sub>2</sub>, -C(CH<sub>2</sub>CH<sub>2</sub>F)<sub>2</sub>NH<sub>2</sub>, -C(CH<sub>2</sub>CH<sub>3</sub>)(CH<sub>2</sub>CF<sub>3</sub>)NH<sub>2</sub>,



or a pharmaceutically acceptable salt or solvate thereof.

8. A compound according to any one of claims 1 to 7 wherein R<sub>6</sub> and R<sub>7</sub> are each C<sub>1</sub>-C<sub>3</sub> alkyl or form a five or six membered carbocyclic ring; or R<sub>6</sub> and R<sub>7</sub> are independently C<sub>1</sub>-C<sub>6</sub>alkyl or C<sub>2</sub>-C<sub>6</sub>alkenyl, in which one or both groups are substituted by one, two, or three halo atoms; or R<sub>6</sub> is hydrogen and R<sub>7</sub> is C<sub>1</sub>-C<sub>6</sub>alkyl, C<sub>2</sub>-C<sub>6</sub>alkenyl which is substituted by one, two, or three halo atoms; or R<sub>6</sub> and R<sub>7</sub> together with the carbon atom to which they are attached may form a C<sub>3</sub>-C<sub>8</sub>cycloalkyl group which is optionally partly unsaturated and which is substituted by one, two, or three halo atoms;
- or a pharmaceutically acceptable salt or solvate thereof.

9. A compound according to any one of claims 1 to 8 wherein R<sub>4</sub> is hydrogen or methyl, or a pharmaceutically acceptable salt or solvate thereof.

10. A compound according to any one of claims 1 to 9 wherein R<sub>5</sub> is hydrogen, C<sub>1</sub>-C<sub>6</sub>alkyl, C<sub>1</sub>-C<sub>6</sub>alkoxy, C<sub>1</sub>-C<sub>6</sub>alkyl

which is substituted by hydroxy or C<sub>1</sub>-C<sub>6</sub>alkyl which is substituted by one, two, or three halo atoms, or a pharmaceutically acceptable salt or solvate thereof.

5        11. A compound according to any one of claims 1 to 10 wherein R<sub>5</sub> is hydrogen, methyl, ethyl, propyl or n-propyl, or a pharmaceutically acceptable salt or solvate thereof.

10        12. A compound according to any one of claims 1 to 11 wherein R<sub>8</sub> is hydrogen, C<sub>1</sub>-C<sub>6</sub>alkyl, (C<sub>1</sub>-C<sub>6</sub>alkyl)<sub>3</sub>-C<sub>8</sub>cycloalkyl, benzyl, 1-phenylethyl, C<sub>1</sub>-C<sub>6</sub>alkyl which is substituted by hydroxy, methoxy, CONH<sub>2</sub>, or CON(CH<sub>3</sub>)<sub>2</sub>, or C<sub>1</sub>-C<sub>6</sub>alkyl which is substituted by one, two, or three halo atoms, phenyl substituted by one, two, or three halo atoms  
15 or benzyl substituted by one, two, or three halo atoms, or a pharmaceutically acceptable salt or solvate thereof.

20        13. A compound according to any one of claims 1 to 12 wherein R<sub>8</sub> is hydrogen, methyl, ethyl or benzyl; or a pharmaceutically acceptable salt or solvate thereof.



25        14. A compound according to any one of claims 1 to 13 wherein R<sub>9</sub> is selected from the group consisting of unsubstituted or substituted thienyl, unsubstituted or substituted naphthyl, unsubstituted or substituted phenoxy and unsubstituted or substituted phenyl; wherein the substituents when present are each independently selected from the group consisting of halo, methyl, ethyl, propyl, t-butyl, trifluoromethyl, trifluoromethoxy, methoxy, ethoxy,  
30 cyano, methylsulphonyl, phenyl, phenoxy, thienyl, pyridyl, thiazolyl, oxazolyl, nitro, CONH<sub>2</sub>, furanyl, benzothiophenyl and benzofuranyl;  
or a pharmaceutically acceptable salt or solvate thereof.

15. A compound of according to claim 14 wherein R9 is selected from phenyl, 4-methylsulphonylphenyl, 3-methylsulphonylphenyl, 4-fluorophenyl, 2-fluorophenyl, 3-fluorophenyl, 3-chlorophenyl, 2-chlorophenyl, 4-chlorophenyl, 4-t-butylphenyl, 4-trifluoromethylphenyl, 3-trifluoromethylphenyl, 4-nitrophenyl, 3-nitrophenyl, 4-bromophenyl, 3-bromophenyl, 2-bromophenyl, 4-methylphenyl, 3-methylphenyl, 4-phenylphenyl, 3-phenylphenyl, 4-phenoxyphenyl, 3-phenoxyphenyl, 4-cyanophenyl, 3-cyanophenyl, 4-carbamoylphenyl, 4-methoxyphenyl, 3-methoxyphenyl, thienyl, thiazolyl, pyridyl, phenoxy, 4-chlorophenoxy, 2,3-dichlorophenyl, 3,4-dichlorophenyl, naphthyl, oxazolyl, 2,4-difluorophenyl, 3,4-difluorophenyl, 3,5-difluorophenyl, 2,3-difluorophenyl, 2,6-difluorophenyl, 2,5-difluorophenyl, 2-fluoro-3-chlorophenyl, 4-ethylphenyl, 4-ethoxyphenyl, 3,4,5-trifluorophenyl, 3-fluoro-4-chlorophenyl and 4-carbamoylphenyl;  
or a pharmaceutically acceptable salt or solvate thereof.


16. A pharmaceutical formulation comprising one or more compounds according to any one of claims 1 to 15 or a pharmaceutically acceptable salt or solvate thereof, and one or more pharmaceutically acceptable diluents or carriers therefor.

17. A pharmaceutical formulation according to claim 16 wherein the formulation further comprises one or more growth hormone secretagogue compounds and/or a bone-antiresorptive agent.

18. A process for producing a compound of Formula I as defined in any one of claims 1 to 15 comprising coupling a compound of Formula XI or XIb

**XI****XI b**


with a compound of formula XIII

**XIII**

5

wherein R1, R2, R3, R4, R5, R6, R7, R8, R9 and Q are as defined in any one of claims 1 to 15.

- 10 19. A process for producing a compound of Formula I as defined in any one of claims 1 to 15 comprising deprotecting a compound of Formula




or

- 15 wherein R2, R3, R4, R5, R6, R7, R8, R9, m and Q are as defined in any one of claims 1 to 12, and PG is an amino protecting group.




20. A process for producing a compound of Formula I as defined in any one of claims 1 to 15 comprising coupling a compound of Formula

5



with a compound of formula XIV

10



wherein R1, R2, R3, R4, R5, R6, R7, R8, R9 and Q are as defined in any one of claims 1 to 15.

15

21. A compound according to any one of claims 1 to 15 for the treatment of the human or animal body by therapy.

22. Use of a compound according to any one of claims 1 to 15 or a pharmaceutically acceptable salt or solvate thereof in the manufacture of a medicament for the treatment of a physiological condition which may be modulated or ameliorated by an increase in endogenous growth hormone.

25

23. A method of using a compound of claim 1 or 2 or a pharmaceutically acceptable salt or solvate thereof for the treatment of a physiological condition which may be modulated or ameliorated by an increase in endogenous growth hormone, which method comprises administering to an animal in need of said treatment an effective amount of a compound of formula I.